NANCY RYAN GRAY

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

LIGAND PHARMACEUTICALS INC

Filing Date Source Excerpt
2018-04-30 Nancy Ryan Gray, Ph.D. Director 2017 58; Expected to be appointed to audit committee after 2018 meeting; 2017 compensation total $360,632.
2019-04-24 Nancy Gray (A) 59 2017 President and CEO of Gordon Research Conferences ... Dr. Gray received 493 restricted stock units with a grant date fair value of $96,584 and 2,474 stock options with a grant date fair value of $186,596. Total: $338,365.

Data sourced from SEC filings. Last updated: 2026-02-03